Welcome to our dedicated page for Bexil news (Ticker: BXLC), a resource for investors and traders seeking the latest updates and insights on Bexil stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bexil's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bexil's position in the market.
Bexil Corporation (Stock Symbol: BXLC) announced the completion of its tender offer on December 2, 2021, accepting 30,288 shares at a price of $25.00 each. Payment for the accepted shares will be processed by the depositary. The firm may pursue further share buybacks at its discretion, potentially through various means including open market transactions. The goal of Bexil is to enhance book value per share over time for its shareholders. This announcement serves informational purposes and does not constitute an offer to purchase shares.
Bexil Corporation (BXLC) reported financial results for Q3 2021, showing net income of approximately $0.14 million or $0.18 diluted EPS, down from $0.40 million or $0.47 diluted EPS in Q3 2020. For the first nine months of 2021, net income was $5.43 million or $6.59 diluted EPS, a turnaround from a net loss of $3.61 million or $4.36 diluted EPS in the same period last year. The book value per share increased to $34.19 from $21.88 a year earlier, highlighting improved shareholder equity.
Bexil Corporation (OTC PINK:BXLC) announced a tender offer inviting shareholders to purchase up to 50,000 shares at $25.00 each. Shareholders can participate until December 2, 2021, at 5:00 p.m. ET. The board has approved this offer but does not make any recommendations on whether to tender shares. The announcement serves informational purposes only and is not an offer to purchase. Bexil aims to enhance book value per share through its investment management activities.
Bexil Corporation (OTC PINK:BXLC) announced its application to subscribe to the OTC Disclosure and News Service. The company aims to qualify its common stock for the OTC Pink Current Information Tier to maintain eligibility for public quotations under Exchange Act Rule 15c2-11. However, there is no guarantee that the application will be accepted or that the company will remain qualified. Bexil focuses on increasing book value per share via its investment management subsidiary, Bexil Advisers LLC, which manages the Dividend and Income Fund (stock symbol: DNIF).
Bexil Corporation (OTC PINK:BXLC) reported strong financial results for Q2 2021, with net income of approximately $3.10 million or $3.69 diluted earnings per share, a significant increase from $1.46 million or $1.74 EPS in Q2 2020. For the first half of 2021, the company achieved a net income of $5.29 million, reversing a net loss of $4.01 million in the same period last year. The book value per share stands at $33.52 based on total equity of $27.8 million.
Bexil Corporation (BXLC) announced its financial results for 2020, reporting a net income of $1.0 million ($1.13 per diluted share), down from $4.51 million ($5.13 per diluted share) in 2019. The company’s book value per share increased by 3% to $27.49, reflecting shareholders' equity of approximately $22.9 million. Bexil's annual meeting is scheduled for June 8, 2021, via conference call, where executives will discuss financial performance and business developments. Investors can access the company’s Annual Report and Proxy Statement on its website.
Bexil Corporation (OTC PINK: BXLC) has announced a tender offer inviting shareholders to sell their shares for $15.00 each, up to an aggregate of 40,000 shares. The offer is set to expire on December 23, 2020, at 5:00 p.m. ET. Shareholders are encouraged to review the offer details carefully and consult with their financial advisors before deciding to participate. The board of directors has approved the offer but does not make any recommendation regarding tendering shares. The tender offer is not an offer to purchase shares in jurisdictions where it would violate local laws.
Bexil Corporation (OTC PINK: BXLC) reported its Q3 2020 financial results, revealing a net income of approximately $0.40 million ($0.47 EPS), down from $0.89 million ($1.03 EPS) in Q3 2019. For the nine months ending September 30, 2020, Bexil faced a net loss of $3.61 million ($4.36 per share), contrasting with a net income of $3.48 million ($3.94 EPS) the previous year. The book value per share is $21.88. The Company noted that the ongoing COVID-19 pandemic has adversely impacted its financial results due to declines in publicly traded securities.
Bexil Corporation (OTC PINK: BXLC) reported financial results for the second quarter ending June 30, 2020. The company recorded a net income of approximately $1.46 million or $1.74 per diluted share, a significant increase from the $0.45 million or $0.50 per diluted share reported in Q2 2019. However, for the first half of 2020, Bexil incurred a net loss of approximately $4.01 million or $4.88 per share, in contrast to a net income of $2.60 million reported for the same period in 2019. The company’s book value per share was $21.86.